2015


Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
2015/№2

Применение новых пероральных антикоагулянтов при проведении электрической кардиоверсии у больных с неклапанной фибрилляцией предсердий

Татарский Б. А., Казеннова Н. В.
ФГБУ "ФМИЦ им. В. А. Алмазова" МЗ РФ, 197341, Санкт-Петербург, ул. Аккуратова, д. 2

Ключевые слова: антикоагулянты, кардиоверсия, ривароксабан, фибрилляция предсердий

DOI: 10.18087/rhj.2015.2.2064

Представлен обзор о возможности применения новых пероральных антикоагулянтов при кардиоверсии по данным крупных контролируемых рандомизированных исследований. Обсуждаются результаты первого исследования использования ривароксабана у пациентов с неклапанной фибрилляцией предсердий при проведении избирательной кардиоверсии.
  1. King DE, Dickerson LM, Sack JL. Acute management of atrial fibrillation: part II. prevention of thromboembolic complications. Am Fam Physician. 2002 Jul 15;66 (2):261–4.
  2. Weigner MJ, Caulfield TA, Danias PG et al. Risk for clinical thromboembolism associ¬ated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997 Apr 15;126 (8):615–20.
  3. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiography study. J Am Coll Cardiol. 1995 Feb;25 (2):452–9.
  4. Gentile F, Elhendy A, Khandheria BK et al. Safety of electrical cardioversion in patients with atrial fibrillation. Mayo Clin Proc. 2002 Sep;77 (9):897–904.
  5. January CT, Wann LS, Alpert JS et al. 2014 AHA / ACC / HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology / American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64 (21):e1–76.
  6. Nuotio I, Hartikainen JE, Grönberg T et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014 Aug 13;312 (6):647–9.
  7. Stiles S. Earliest Is Best for Preventing Thromboembolism in No-Anticoagulant Acute AF Cardioversion: Cohort Study. MedScape. 2014 Aug 12. Available at: http://www.medscape. com / viewarticle / 829805.
  8. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special condition of the European Heart Rhythm Assotiation. Eur Heart J. 2012 Nov;33 (21):2719–47.
  9. Calkins H, Kuck KH, Cappato R et al. 2012 HRS / EHRA / ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012 Apr;14 (4):528–606.
  10. Prystowsky EN, Benson DW, Fuster V et al. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996 Mar 15;93 (6):1262–77.
  11. Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011 Jan 18;123 (2):131–6.
  12. Piccini JP, Stevens SR, Lokhnygina Y et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013 May 14;61 (19):1998–2006.
  13. Flaker G, Lopes RD, Al-Khatib SM et al. Efficacy and safety of apixa­ban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014 Mar 25;63 (11):1082–7.
  14. Ezekowitz MD, Cappato R, Klein AL et al. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvularaTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation under­going elective cardioversion. Am Heart J. 2014 May;167 (5):646–52.
  15. Cappato R, Ezekowitz MD, Klein AL et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014 Dec 14;35 (47):3346–55.
Татарский Б. А., Казеннова Н. В. Применение новых пероральных антикоагулянтов при проведении электрической кардиоверсии у больных с неклапанной фибрилляцией предсердий. Сердце: журнал для практикующих врачей. 2015;14 (2):104–109

Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
Ru En